What “Clinically Necessary” Actually Means on Your Chart
Since the shortage ended, compounding requires a documented reason the approved product will not work for you specifically. Most patients have never seen what is written in their own record.
The short version
- With shortages resolved, cost and convenience are not legal justifications for compounding.
- A documented, patient-specific reason the FDA-approved product is unsuitable is what the standard requires.
- Legitimate examples include a documented allergy to an inactive ingredient, or a need for a dosage form that is not commercially available.
- You can request your own records and read what was written. Most patients never do.
Between 2022 and 2025 the justification for a compounded GLP-1 prescription was simple: the drug was in shortage, and federal law permits compounding shortage drugs. Once the FDA declared those shortages resolved, that reasoning stopped working, and the standard reverted to something much narrower — a specific, documented medical reason that the approved product does not work for you.
What does not count
These are the reasons most patients actually have, and none of them satisfies the standard:
- The brand-name drug costs more
- Your insurance denied coverage
- The compounded version is more convenient to obtain
- You prefer the telehealth provider's service
- You want a dose between the manufacturer's standard increments, without a documented clinical reason for that particular dose
Cost is the difficult one, because for many people it is a genuine barrier. It is still not a compounding justification under the current framework, and a provider that tells you otherwise is describing how the market has operated rather than what the rules say.
A documented allergy or intolerance to an inactive ingredient in the approved product. A need for a dosage form that is not commercially available. A documented clinical requirement for a strength the manufacturer does not produce. The common thread is that the reason attaches to you as an individual patient and is written in your record.
Why the documentation is on your chart, not the pharmacy's
The determination is a prescriber judgement. Your clinician is the one who decides that the approved product is unsuitable for you and records why. The pharmacy compounds against that prescription. If the reasoning is thin, the exposure sits with the prescriber — and the practical consequence lands on you when the arrangement stops.
How to read your own record
You have a right to your medical records. Request them from the telehealth provider directly and look for:
- The stated clinical reason for compounded rather than approved product
- Whether that reason is specific to you or boilerplate identical for every patient
- Whether any allergy or intolerance is documented, and whether you actually reported one
- Whether the record reflects an actual clinician review rather than an automated approval
- Whether the formulation, including additives, is justified anywhere
If the entry is generic text that could apply to anyone, you have learned something meaningful about the strength of your prescription's foundation.
Providers with clinician review and brand-name pathways
Every provider below is a paid partner. Pricing changes frequently — confirm current cost on the provider's own page before you enrol.
Marketplace for cash-pay appointments with clinicians who prescribe FDA-approved brand-name medication only — Rybelsus, the oral Wegovy pill, and Foundayo. No compounded product.
See Sesame Care pricing Paid partner linkSemaglutide injection through a licensed US telehealth network. Injectable only — no oral formulation offered.
See Embody pricing Paid partner linkTelehealth intake with both injectable and oral pathways in the questionnaire flow.
See Care Bare Rx pricing Paid partner linkThe additive question, again
The industry's answer to the necessity standard was to add ingredients and describe the result as personalised. IQVIA found more than 80% of compounded semaglutide and tirzepatide prescriptions contained supplemental ingredients such as B vitamins or levocarnitine, and noted these may serve as a rationale for continued compounding despite resolved shortages. The FDA's position is that you cannot simply add extras and call the product different — the medical necessity has to be real and documented for the individual patient.
So if your vial contains B12, the relevant question is not whether B12 is safe. It is whether anybody established that you needed it before it was added.
Ask your prescriber directly: what is documented in my chart as the clinical reason I am on a compounded product rather than the approved one? A clinician who can answer immediately has thought about it. Silence or deflection is its own answer.
Why this is worth your attention now
On April 30, 2026 the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List on a finding that there is no longer a clinical need for certain compounded versions. If that finalises, the mass-market route closes and what remains is patient-specific compounding backed by genuine documentation. Patients whose charts contain real clinical reasoning will likely keep access. Patients whose charts contain a template sentence will not.
Sources
- Federal Food, Drug, and Cosmetic Act provisions governing compounding and shortage-list eligibility.
- FDA proposed rule on 503B Bulks List status, April 30, 2026.
- IQVIA analysis of supplemental ingredients in compounded GLP-1 prescriptions.
- Medscape and Pharmacy Times coverage of post-shortage compounding requirements, 2026.
- US Food and Drug Administration warning letters to telehealth companies, February 2026.